Re: Farmas USA
AMRN
Lo que nos preguntábamos el otro día sobre la contabilización de las ventas:
In accordance with U.S. Generally Accepted Accounting Principles (US GAAP), and consistent with Q1 reporting, until the company has more operating history with the commercialization of Vascepa, it is recognizing revenue based not on its sales to wholesalers but based on the resale of Vascepa for the purpose of filling prescriptions. For the six months ended June 30, 2013, the net value of Vascepa sold to wholesalers was $9.6 million, and, as a result, in addition to $7.8 million in recognized revenue, Amarin recorded deferred revenue of $1.8 million at June 30, 2013. Cash collections from the sale of Vascepa in the quarter ended June 30, 2013 were approximately $6.6 million for a total of $9.4 million collected from wholesalers since the launch of Vascepa.
the net price of Vascepa for the six months ended June 30, 2013 reflects the deduction of one-time discounts paid to wholesalers to stock Vascepa in advance of Vascepa’s launch in January 2013, as well as the costs of a co-payment rebate card program
Operational priorities in the second half of 2013 are (además de las obvias):
-Continuing development of a fixed-dose combination of Vascepa and a leading statin
-Submitting an sNDA for a fourth API supplier
- Publishing additional data from Amarin’s clinical trials
Otra cosa que no acabábamos de tener clara:
During Q2, the FDA accepted Amarin’s sNDA for the ANCHOR indication, a precondition for which was that the REDUCE-IT cardiovascular outcomes study be substantially underway
Consistent with Amarin’s Special Protocol Assessment (SPA) agreement, and based on the company’s discussions with the FDA, the company does not believe the final results of the REDUCE-IT study will be required for FDA approval of Vascepa for the ANCHOR indication, although there can be no assurance that this will be the case Amarin reported net product revenues for the quarter ended June 30, 2013 of $5.5 million as compared to revenue of $2.3 million for the quarter ended March 31, 2013
Datos económicos
Amarin beats by $0.04, misses on revenues • 4:35 PM
Amarin (AMRN): Q2 EPS of -$0.36 beats by $0.04.
Revenue of $5.5M misses by $2.73M. (PR)
net loss of $101.9 million, or basic and diluted loss per share of $0.68
Amarin reported cash and cash equivalents decreased in aggregate by $110.8 million from December 31, 2012 as compared to June 30, 2013
During the six months ended June 30, 2013, net cash outflows included approximately $48.2 million paid for sales and marketing related expenses in conjunction with the initial commercial launch of Vascepa, approximately $16.7 million paid in support of the REDUCE-IT cardiovascular outcomes study and approximately $16.3 million for Vascepa API, purchased in conjunction with the buildup of commercial supply and for clinical trial material.
$3.0 million was included as a component of research and development expense
Edito: y ahora estoy con la conferencia y es sencillamente cojonuda en cuanto a exposición de la información. Aclara todas las dudas sobre los rumores clínicos infundados y es una delicia para el inversor.
«Después de nada, o después de todo/ supe que todo no era más que nada.»
